14-day Premium Trial Subscription Sign Up For FreeGet Free

Windtree Therapeutics Inc Stock Forecast NASDAQ:WINT

Price Target and Analyst Ratings

Most Recent Rating

Oppenheimer is very positive about WINT and gave it a "Outperform" rating on June 04, 2021. The price target was set to $8.00.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-06-04 Outperform Initiated by Oppenheimer $2.70 $8.00
2021-06-04 Outperform Initiated by Oppenheimer $2.70

WINT Stock Trend

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -9.14% during the next 3 months and, with a 90% probability hold a price between $1.43 and $1.75 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-30 $1.57 $1.75 $1.92
2021-10-01 $1.57 $1.75 $1.92
2021-10-04 $1.57 $1.74 $1.92
2021-10-05 $1.56 $1.74 $1.92
2021-10-06 $1.56 $1.74 $1.91
2021-10-07 $1.56 $1.73 $1.91
2021-10-08 $1.56 $1.73 $1.91
2021-10-11 $1.55 $1.73 $1.90
2021-10-12 $1.55 $1.72 $1.90
2021-10-13 $1.55 $1.72 $1.90
2021-10-14 $1.54 $1.72 $1.89
2021-10-15 $1.54 $1.72 $1.89
2021-10-18 $1.54 $1.71 $1.89
2021-10-19 $1.53 $1.71 $1.88
2021-10-20 $1.53 $1.71 $1.88
2021-10-21 $1.53 $1.70 $1.88
2021-10-22 $1.52 $1.70 $1.88
2021-10-25 $1.52 $1.70 $1.87
2021-10-26 $1.52 $1.69 $1.87
2021-10-27 $1.52 $1.69 $1.87
2021-10-28 $1.51 $1.69 $1.86
2021-10-29 $1.51 $1.68 $1.86
2021-11-01 $1.51 $1.68 $1.86
2021-11-02 $1.50 $1.68 $1.85
2021-11-03 $1.50 $1.68 $1.85
2021-11-04 $1.50 $1.67 $1.85
2021-11-05 $1.49 $1.67 $1.84
2021-11-08 $1.49 $1.67 $1.84
2021-11-09 $1.49 $1.66 $1.84
2021-11-10 $1.48 $1.66 $1.84

About Windtree Therapeutics Inc

Windtree Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform produces a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant — and novel drug-delivery technologies being developed to enable noninvasive administration of aerosoliz... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT